Hope for boys with muscular dystrophy: 2-Year drug extension study seeks to control debilitating disease
NCT ID NCT07209332
Summary
This study follows boys with Duchenne muscular dystrophy who previously received the experimental drug WVE-N531 to see how safe and effective it is over two years. All 175 participants will continue receiving monthly intravenous doses of the drug while researchers monitor their health, muscle function, and mobility. The goal is to understand if long-term treatment can help control this progressive muscle-wasting disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Istiklal Hospital/ Clinical Research Unit
Amman, Jordan
-
Oxford Children's Hospital, Oxford University Hospitals NHS Foundation Trust
Headington, Oxford, OX3 9DU, United Kingdom
-
The Specialty Hospital (TSH)/ Advanced Clinical Center
Amman, Jordan
Conditions
Explore the condition pages connected to this study.